106 filings
Page 2 of 6
6-K
c571fsab
6 Jul 23
Current report (foreign)
8:11am
6-K
ml08e6l hkg
6 Jul 23
Current report (foreign)
7:59am
6-K
3wj rqxev
3 Jul 23
Current report (foreign)
4:15pm
6-K
y5q9flgg1gs42wjsk
22 Jun 23
Aslan Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab In Japan
8:32am
6-K
oddf5252tezuojjtxlk
28 Apr 23
Aslan Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:29am
6-K
x7fxt2q41fec8m3ez5
24 Mar 23
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
7:02am
6-K
kqyurc yov9tw1fs7
10 Mar 23
Aslan Pharmaceuticals Announces Plan to Implement Ads Ratio Change
7:30am
6-K
f66pj41i2zbwhbumqv
24 Feb 23
Unit Purchase Agreement
10:27am
6-K
ubiuiffwgj1ee0bg
31 Jan 23
Current report (foreign)
6:02am
6-K
4j67h qdt
4 Jan 23
Current report (foreign)
6:02am
6-K
y0o1td3
21 Dec 22
Current report (foreign)
6:03am
6-K
8a1yz
28 Oct 22
Aslan Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:01am
6-K
aekkvz7mn8zflt0i
28 Sep 22
Current report (foreign)
9:01am
6-K
1etog4c7 08dpw251
14 Sep 22
Current report (foreign)
7:45am
6-K
1mjwv
13 Sep 22
Amendment No. 1 to the Open Market Sale Agreementsm
4:31pm
6-K
6iy13jea gkojy
8 Sep 22
Current report (foreign)
7:01am
6-K
ve5w6dcvef 72fk6
12 Aug 22
Aslan Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
6:54am
6-K
2pssodznqlxqdd8w49le
27 Apr 22
Aslan Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:00am
6-K
jq17n05wjyqxgj4
1 Apr 22
Aslan Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
5:00pm
6-K
gqwzgv8xc4 gc
25 Mar 22
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
7:05am